Welcome to our dedicated page for Shoulder Innovations SEC filings (Ticker: SI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shoulder Innovations filings document a Delaware medical technology issuer focused on shoulder arthroplasty implants and related surgical-care technologies. Form 8-K reports cover operating results, Regulation FD disclosures, product-launch announcements, FDA-cleared indications, strategic partnership announcements, and material agreements tied to corporate facilities.
Governance filings include the definitive proxy statement for the annual meeting, director elections, board committee matters, non-employee director compensation, and stockholder voting procedures. Current reports also record director appointments, resignations, independence determinations, indemnification arrangements and other corporate-governance events.
Shoulder Innovations, Inc. reported that officer David Lawrence Blue received a grant of stock options on January 30, 2026. The award covers 88,450 options for common stock at an exercise price of $14.16 per share, all held as a direct ownership position.
The options vest in four equal annual installments. One-fourth of the underlying shares will vest on March 1 each year, beginning March 1, 2027, until fully vested. After this grant, Blue beneficially owns 88,450 derivative securities in the form of these stock options.
Shoulder Innovations, Inc. granted stock options to its CEO and Executive Chairman, Robert Joseph Ball. On January 30, 2026, he received a stock option covering 265,351 shares of common stock at an exercise price of $14.16 per share.
The option was granted directly to him and is scheduled to vest in four equal annual installments. One-fourth of the underlying shares will vest on March 1 each year, beginning on March 1, 2027, which spreads the potential ownership benefit over several years.
Shoulder Innovations, Inc. disclosed a new stock option grant to Chief Operating Officer and director Matthew Fraser Ahearn. On January 30, 2026, he received an option covering 88,450 shares of common stock at an exercise price of $14.16 per share.
According to the vesting terms, the option vests in four equal annual installments. One-fourth of the underlying shares will vest on March 1 each year, beginning on March 1, 2027, aligning the award with multi-year executive retention and performance incentives.
Shoulder Innovations, Inc. Chief Financial Officer Jeffrey S. Points reported acquiring common stock through the company’s 2025 Employee Stock Purchase Plan. On December 31, 2025, he acquired 1,076 shares of common stock at a purchase price of $12.16 per share, which the plan set at 85% of the closing price of the stock on that date. Following this transaction, he beneficially owned 55,521 common shares directly, and an additional 50 shares indirectly held by his son.
Shoulder Innovations, Inc. officer David Lawrence Blue reported buying common stock through the company’s 2025 Employee Stock Purchase Plan. On December 31, 2025, he acquired 1,041 shares of common stock at $12.16 per share, a price set at 85% of the closing price that day under the ESPP rules. After this transaction, he beneficially owned 139,372 shares, held directly. Blue serves as the company’s Chief Customer Experience Officer, and the filing notes that this is a voluntary report of the ESPP purchase.
Shoulder Innovations, Inc. CEO & Executive Chairman Robert Joseph Ball reported acquiring additional common stock through the company’s 2025 Employee Stock Purchase Plan. On December 31, 2025, he acquired 1,661 shares of common stock at a purchase price of $12.16 per share, which the plan set at 85% of the closing price of the company’s common stock on that date. Following this ESPP purchase, Ball beneficially owned 120,118 shares of Shoulder Innovations common stock held directly.
Shoulder Innovations, Inc. director and Chief Operating Officer Matthew Fraser Ahearn reported acquiring common stock through the company’s 2025 Employee Stock Purchase Plan (ESPP). On December 31, 2025, he acquired 477 shares of common stock at a purchase price of $12.16 per share, which the ESPP sets at 85% of the closing price of the stock on that date. Following this transaction, he beneficially owned 215,856 shares of Shoulder Innovations common stock in direct ownership.
Shoulder Innovations, Inc. Chief Financial Officer Jeffrey S. Points reported acquiring additional company stock. On 12/11/2025 he acquired 995 common shares at $14.65 per share, and on 12/12/2025 he acquired 1,005 shares at $14.98. Following these transactions, he directly owned 54,445 common shares. He also reported indirect beneficial ownership of 50 shares held by his son.
Shoulder Innovations, Inc.'s CEO and Executive Chairman, who also serves as a director, reported purchasing additional common stock. On December 11, 2025, the insider bought 3,300 shares at a weighted average price of $14.8285 per share, followed by 3,900 shares on December 12, 2025 at a weighted average price of $14.8911. After these transactions, the insider directly owned 118,457 shares of Shoulder Innovations common stock.
Shoulder Innovations, Inc. reported that it has entered into a strategic partnership with Interventional Systems to bring a robotic platform to shoulder arthroplasty procedures. The collaboration aims to pair Shoulder Innovations’ implant and surgical know-how with Interventional Systems’ robotics technology to support more precise shoulder replacement surgery. The news was shared through a press release furnished under a current report, meaning it provides an operational and strategic update rather than new financial results.